OXYMORPHONE

Oxymorphone Adverse Events Reported to the FDA Over Time

How are Oxymorphone adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Oxymorphone, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Oxymorphone is flagged as the suspect drug causing the adverse event.

Most Common Oxymorphone Adverse Events Reported to the FDA

What are the most common Oxymorphone adverse events reported to the FDA?

Drug Abuse	331 (4.77%)
Drug Ineffective	273 (3.94%)
Intentional Drug Misuse	202 (2.91%)
Drug Toxicity	167 (2.41%)
Wrong Technique In Drug Usage Proce...	150 (2.16%)
Overdose	120 (1.73%)
Nausea	107 (1.54%)
Incorrect Route Of Drug Administrat...	99 (1.43%)
Vomiting	98 (1.41%)
Accidental Death	96 (1.38%)
Drug Effect Decreased	89 (1.28%)
	Show More
Inappropriate Schedule Of Drug Admi...	85 (1.23%)
Drug Dependence	82 (1.18%)
Withdrawal Syndrome	82 (1.18%)
Cardiac Arrest	77 (1.11%)
Death	77 (1.11%)
Unresponsive To Stimuli	75 (1.08%)
Completed Suicide	74 (1.07%)
Drug Diversion	74 (1.07%)
Respiratory Arrest	70 (1.01%)
Headache	60 (.87%)
Insomnia	58 (.84%)
Loss Of Consciousness	58 (.84%)
Pain	58 (.84%)
Feeling Abnormal	55 (.79%)
Drug Withdrawal Syndrome	54 (.78%)
Diarrhoea	52 (.75%)
Accidental Overdose	51 (.74%)
Malaise	51 (.74%)
Pulmonary Congestion	51 (.74%)
Constipation	50 (.72%)
Dizziness	49 (.71%)
Medication Residue	49 (.71%)
Pulmonary Oedema	49 (.71%)
Drug Screen Positive	43 (.62%)
Confusional State	39 (.56%)
Dyspnoea	39 (.56%)
Convulsion	38 (.55%)
Somnolence	35 (.5%)
Abdominal Pain Upper	34 (.49%)
Multiple Drug Overdose	33 (.48%)
Contusion	32 (.46%)
Abdominal Discomfort	31 (.45%)
Drug Dispensing Error	31 (.45%)
Inadequate Analgesia	31 (.45%)
Multiple Drug Overdose Accidental	31 (.45%)
Road Traffic Accident	31 (.45%)
Poisoning	30 (.43%)
Depression	29 (.42%)
Agitation	28 (.4%)
Chest Pain	28 (.4%)
Drug Screen Negative	28 (.4%)
Hallucination	26 (.37%)
Respiratory Depression	26 (.37%)
Tinnitus	25 (.36%)
Anxiety	24 (.35%)
Fatigue	24 (.35%)
Oedema Peripheral	24 (.35%)
Weight Decreased	24 (.35%)
Alcohol Poisoning	23 (.33%)
Hyperhidrosis	23 (.33%)
Pruritus	23 (.33%)
Dehydration	22 (.32%)
Substance Abuse	22 (.32%)
Fall	21 (.3%)
Incorrect Dose Administered	21 (.3%)
Cardio-respiratory Arrest	20 (.29%)
Cardiomegaly	20 (.29%)
Drug Interaction	20 (.29%)
Skin Laceration	20 (.29%)
Abdominal Pain	19 (.27%)
Cyanosis	19 (.27%)
Decreased Appetite	19 (.27%)
Dysphagia	19 (.27%)
Euphoric Mood	19 (.27%)
Hypotension	19 (.27%)
Tremor	19 (.27%)
Abnormal Behaviour	18 (.26%)
Brain Oedema	18 (.26%)
Migraine	18 (.26%)
Suicidal Ideation	18 (.26%)
Arteriosclerosis Coronary Artery	17 (.25%)
Facial Bones Fracture	17 (.25%)
Muscle Spasms	17 (.25%)
Periorbital Haematoma	17 (.25%)
Condition Aggravated	16 (.23%)
Drug Abuser	16 (.23%)
Hypersensitivity	16 (.23%)
Product Formulation Issue	16 (.23%)
Self-medication	16 (.23%)
Back Pain	15 (.22%)
Depressed Level Of Consciousness	15 (.22%)
Disorientation	15 (.22%)
Haemoptysis	15 (.22%)
Hepatic Congestion	15 (.22%)
Irritability	15 (.22%)
Nervousness	15 (.22%)
Palpitations	15 (.22%)
Pancreatitis	15 (.22%)
Pyrexia	15 (.22%)
Chest Discomfort	14 (.2%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Oxymorphone, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oxymorphone is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Oxymorphone

What are the most common Oxymorphone adverse events reported to the FDA?

Psychiatric	733 (10.57%)
Medication Errors	676 (9.75%)
Therapeutic And Nontherapeutic Effe...	503 (7.25%)
Neurological	364 (5.25%)
Gastrointestinal Signs	350 (5.05%)
Chemical Injury And Poisoning	248 (3.58%)
Respiratory	226 (3.26%)
Injuries	188 (2.71%)
Fatal Outcomes	176 (2.54%)
Cardiac Arrhythmias	125 (1.8%)
Lower Respiratory Tract Disorders	122 (1.76%)
	Show More
Gastrointestinal Motility And Defec...	118 (1.7%)
Product Quality Issues	114 (1.64%)
Suicidal And Self-injurious Behavio...	107 (1.54%)
Legal Issues	100 (1.44%)
Toxicology And Therapeutic Drug Mon...	88 (1.27%)
Anxiety Disorders	78 (1.12%)
Headaches	78 (1.12%)
Sleep Disorders	76 (1.1%)
Epidermal And Dermal Conditions	67 (.97%)
Lifestyle Issues	60 (.87%)
Hepatic And Hepatobiliary	58 (.84%)
Infections - Pathogen Unspecified	58 (.84%)
Mood Disorders	55 (.79%)
Deliria	54 (.78%)
Disturbances In Thinking	52 (.75%)
Cardiac And Vascular Investigations	50 (.72%)
Muscle	48 (.69%)
Coronary Artery	47 (.68%)
Cardiac Disorder Signs	43 (.62%)
Depressed Mood Disorders	42 (.61%)
Musculoskeletal And Connective Tiss...	40 (.58%)
Physical Examination Topics	40 (.58%)
Seizures	38 (.55%)
Skin Appendage Conditions	38 (.55%)
Myocardial	34 (.49%)
Inner Ear And Viiith Cranial Nerve	33 (.48%)
Procedural And Device Related Injur...	33 (.48%)
Movement Disorders	32 (.46%)
Renal Disorders	31 (.45%)
Therapeutic Procedures And Supporti...	31 (.45%)
Mental Impairment	28 (.4%)
Bone And Joint Injuries	27 (.39%)
Urinary Tract Signs	27 (.39%)
Appetite And General Nutritional	26 (.37%)
Decreased And Nonspecific Blood Pre...	26 (.37%)
Electrolyte And Fluid Balance Condi...	25 (.36%)
Exocrine Pancreas Conditions	25 (.36%)
Gastrointestinal Hemorrhages	25 (.36%)
Allergic Conditions	24 (.35%)
Arteriosclerosis, Stenosis, Vascula...	24 (.35%)
Bronchial Disorders	24 (.35%)
Personality Disorders	24 (.35%)
Vision	22 (.32%)
Bacterial Infectious	20 (.29%)
Increased Intracranial Pressure And...	20 (.29%)
Upper Respiratory Tract Disorders	20 (.29%)
Joint	19 (.27%)
Sleep Disturbances	19 (.27%)
Psychiatric And Behavioural Symptom...	18 (.26%)
Angiedema And Urticaria	16 (.23%)
Body Temperature Conditions	15 (.22%)
Changes In Physical Activity	15 (.22%)
Spleen, Lymphatic And Reticulendoth...	15 (.22%)
Viral Infectious	15 (.22%)
Gastrointestinal Conditions	14 (.2%)
Hematology Investigations	14 (.2%)
Skin Vascular Abnormalities	14 (.2%)
Acid-base	13 (.19%)
Fungal Infectious	13 (.19%)
Hepatobiliary	13 (.19%)
Manic And Bipolar Mood Disorders	13 (.19%)
Enzyme	12 (.17%)
Gastrointestinal Stenosis And Obstr...	12 (.17%)
Hearing	12 (.17%)
Metabolic, Nutritional And Blood Ga...	12 (.17%)
Structural Brain	12 (.17%)
Vascular Hemorrhagic	12 (.17%)
Water, Electrolyte And Mineral	12 (.17%)
Heart Failures	11 (.16%)
Dental And Gingival Conditions	10 (.14%)
Eye	10 (.14%)
Gastrointestinal Ulceration And Per...	10 (.14%)
Oral Soft Tissue Conditions	10 (.14%)
Peripheral Neuropathies	10 (.14%)
Bone Disorders	9 (.13%)
Glucose Metabolism Disorders	8 (.12%)
Nephropathies	8 (.12%)
Sexual Function And Fertility	8 (.12%)
Tongue Conditions	8 (.12%)
Administration Site Reactions	7 (.1%)
Central Nervous System Vascular	7 (.1%)
Communication Disorders	7 (.1%)
Dissociative	7 (.1%)
Neurological, Special Senses And Ps...	7 (.1%)
Neuromuscular	7 (.1%)
Ocular Infections, Irritations And ...	7 (.1%)
Vascular Hypertensive	7 (.1%)
Platelet	6 (.09%)
Salivary Gland Conditions	6 (.09%)
Uterine, Pelvic And Broad Ligament	6 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Oxymorphone, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oxymorphone is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.